SMARCB1 and neoplasm: By inhibiting the ErbB2-EGFR pathway, lapatinib can effectively suppress the activity of central nervous system atypical teratoid/rhabdoid tumor (CNS ATRT) tumor cells harboring INI1 mutations, both in vitro and in vivo (14).